The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Soliris (eculizumab; Alexion) for use in patients with neuromyelitis optica spectrum disorder (NMSOD), a complement-mediated disorder of the central nervous system.
Ook interessant voor je
